{
  "id": "mhgap#risk_safety_330d7fd0",
  "content": "route of administration, or from a combination of the individual’s dignity, and never using humiliating\nthese. The risk may be related to short-term effects or degrading interventions – in line with the WHO\nof the substance or to longer-term cumulative and United Nations Office on Drugs and Crime\neffects on physical or mental health or functioning. (UNODC) International standards for the treatment\nHazardous drug use has not yet reached the level of of drug use disorders (147), as shown in Box 3.1.\nhaving caused harm to physical or mental health of\nthe user or others around the user.\n65\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nBOX 3.1 Ethical standards for providing treatment of support to people using drugs or\nwith drug use disorders\n▶ The patients should grant informed consent before treatment begins and have a guaranteed option to\nwithdraw from treatment at any time.\n▶ Patient data should be strictly confidential. Circumventing the confidentiality of health records in order\nto register patients entering treatment should be prohibited.\n▶ Legislative measures, supported by appropriate staff training and service rules and regulations, should\nensure and protect the confidentiality of patient data.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "management",
      "psychoeducation"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety route of administration, or from a combination of the individual’s dignity, and never using humiliating\nthese. The risk may be related to short-term effects or degrading interventions – in line with the WHO\nof the substance or to longer-term cumulative and United Nations Office on Drugs and Crime\neffects on physical or mental health or functioning. (UNODC) International standards for the treatment\nHazardous drug use has not yet reached the level of of drug use disorders (147), as shown in Box 3.1.\nhaving caused harm to physical or mental health of\nthe user or others around the user.\n65\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nBOX 3.1 Ethical standards for providing treatment of support to people using drugs or\nwith drug use disorders\n▶ The patients should grant informed consent before treatment begins and have a guaranteed option to\nwithdraw from treatment at any time.\n▶ Patient data should be strictly confidential. Circumventing the confidentiality of health records in order\nto register patients entering treatment should be prohibited.\n▶ Legislative measures, supported by appropriate staff training and service rules and regulations, should\nensure and protect the confidentiality of patient data. Route of administration, or from a combination of the individual’s dignity, and never using humiliating\nthese. the nguy cơ may be related to short-term effects or degrading interventions – in line with the who\nof the sub..."
}